From the Departments of Psychiatry (R.M.C., K.E.F., B.C.S., E.H.R.) and Medicine (P.K.S., R.J.K., M.W.R.), Washington University School of Medicine, Saint Louis, Missouri; Cardiovascular Health Research Center (W.S.H.), Sanford Research, University of South Dakota, Sioux Falls, South Dakota.
This study was supported, in part, by Grant RO1 HL076808 (R.M.C.) from the National Heart, Lung, and Blood Institute, and The Lewis and Jean Sachs Charitable Lead Trust.
Dr. Carney, or a member of his family, owns stock in Pfizer, Inc. Dr. Harris is a scientific advisor to GlaxoSmithKline, Monsanto, and Unilever. He is a speaker for GlaxoSmithKline and a stockholder in OmegaQuant Analytics. In 2009, he founded OmegaQuant, LLC, which sells the red blood cell fatty acid assay used in this study. Drs. Freedland, Rich, Krone, Rubin, and Mr. Steinmeyer have not disclosed any potential conflicts of interest.
Address correspondence and reprint requests to Robert M. Carney, PhD, Behavioral Medicine Center, Department of Psychiatry, Washington University School of Medicine, 4320 Forest Park Avenue, Suite 301, St. Louis, MO 63108. E-mail: [email protected]
Received for publication February 15, 2010; revision received May 19, 2010.